Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies
CONCLUSION: The experience from our single institution pilot study suggested that sequential rather than alternating BR and cytarabine/rituximab (CR) was easier to administer from the standpoint of toxicities and subsequent dose modifications. Safety and efficacy data from the 2 pilot studies, FitMCL 1.0 and 2.0, were similar. The pilot studies provided preliminary safety data supporting the development of the NCTN trial EA4181, assessing three different induction regimens with or without acalabrutinib.PMID:37183115 | DOI:10.1016/j.clml.2023.04.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 14, 2023 Category: Cancer & Oncology Authors: Dilan A Patel Fei Wan Kathryn Trinkaus Daniel G Guy Natasha Edwin Marcus Watkins Nancy L Bartlett Amanda Cashen Todd A Fehniger Armin Ghobadi Neha-Mehta Shah Brad S Kahl Source Type: research
Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors
CONCLUSIONS: HBV reactivation risk is intermediate in patients with past HBV infection who receive BTK inhibitors. For patients with past HBV infection who received BTK inhibitors, data are insufficient to recommend universal anti-HBV prophylaxis, but monitoring for HBV reactivation is warranted.PMID:37150651 | DOI:10.1016/j.clml.2023.04.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 7, 2023 Category: Cancer & Oncology Authors: Chia-Yu Chiu Sairah Ahmed Sheeba K Thomas Lan Sun Wang Khalis Mustafayev Luis E Fayad William G Wierda Fareed Khawaja Harrys A Torres Source Type: research
Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors
CONCLUSIONS: HBV reactivation risk is intermediate in patients with past HBV infection who receive BTK inhibitors. For patients with past HBV infection who received BTK inhibitors, data are insufficient to recommend universal anti-HBV prophylaxis, but monitoring for HBV reactivation is warranted.PMID:37150651 | DOI:10.1016/j.clml.2023.04.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 7, 2023 Category: Cancer & Oncology Authors: Chia-Yu Chiu Sairah Ahmed Sheeba K Thomas Lan Sun Wang Khalis Mustafayev Luis E Fayad William G Wierda Fareed Khawaja Harrys A Torres Source Type: research
Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors
CONCLUSIONS: HBV reactivation risk is intermediate in patients with past HBV infection who receive BTK inhibitors. For patients with past HBV infection who received BTK inhibitors, data are insufficient to recommend universal anti-HBV prophylaxis, but monitoring for HBV reactivation is warranted.PMID:37150651 | DOI:10.1016/j.clml.2023.04.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 7, 2023 Category: Cancer & Oncology Authors: Chia-Yu Chiu Sairah Ahmed Sheeba K Thomas Lan Sun Wang Khalis Mustafayev Luis E Fayad William G Wierda Fareed Khawaja Harrys A Torres Source Type: research
Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors
CONCLUSIONS: HBV reactivation risk is intermediate in patients with past HBV infection who receive BTK inhibitors. For patients with past HBV infection who received BTK inhibitors, data are insufficient to recommend universal anti-HBV prophylaxis, but monitoring for HBV reactivation is warranted.PMID:37150651 | DOI:10.1016/j.clml.2023.04.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 7, 2023 Category: Cancer & Oncology Authors: Chia-Yu Chiu Sairah Ahmed Sheeba K Thomas Lan Sun Wang Khalis Mustafayev Luis E Fayad William G Wierda Fareed Khawaja Harrys A Torres Source Type: research
Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors
CONCLUSIONS: HBV reactivation risk is intermediate in patients with past HBV infection who receive BTK inhibitors. For patients with past HBV infection who received BTK inhibitors, data are insufficient to recommend universal anti-HBV prophylaxis, but monitoring for HBV reactivation is warranted.PMID:37150651 | DOI:10.1016/j.clml.2023.04.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 7, 2023 Category: Cancer & Oncology Authors: Chia-Yu Chiu Sairah Ahmed Sheeba K Thomas Lan Sun Wang Khalis Mustafayev Luis E Fayad William G Wierda Fareed Khawaja Harrys A Torres Source Type: research
Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors
CONCLUSIONS: HBV reactivation risk is intermediate in patients with past HBV infection who receive BTK inhibitors. For patients with past HBV infection who received BTK inhibitors, data are insufficient to recommend universal anti-HBV prophylaxis, but monitoring for HBV reactivation is warranted.PMID:37150651 | DOI:10.1016/j.clml.2023.04.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 7, 2023 Category: Cancer & Oncology Authors: Chia-Yu Chiu Sairah Ahmed Sheeba K Thomas Lan Sun Wang Khalis Mustafayev Luis E Fayad William G Wierda Fareed Khawaja Harrys A Torres Source Type: research
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study
CONCLUSION: Ixazomib is a feasible and effective maintenance option for prolonging PFS across this heterogeneous patient population.PMID:37149398 | DOI:10.1016/j.clml.2023.03.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 6, 2023 Category: Cancer & Oncology Authors: Sara Bringhen Lud ěk Pour Reuben Benjamin Sebastian Grosicki Chang-Ki Min Danielle Leao C de Farias Alexander Vorog Richard J Labotka Bingxia Wang Dasha Cherepanov Lauren E Cain Sudhakar Manne S Vincent Rajkumar Meletios A Dimopoulos Source Type: research
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study
CONCLUSION: Ixazomib is a feasible and effective maintenance option for prolonging PFS across this heterogeneous patient population.PMID:37149398 | DOI:10.1016/j.clml.2023.03.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 6, 2023 Category: Cancer & Oncology Authors: Sara Bringhen Lud ěk Pour Reuben Benjamin Sebastian Grosicki Chang-Ki Min Danielle Leao C de Farias Alexander Vorog Richard J Labotka Bingxia Wang Dasha Cherepanov Lauren E Cain Sudhakar Manne S Vincent Rajkumar Meletios A Dimopoulos Source Type: research
Prognostic Role of CDKN2A Deletion and p53 Expression and Association With MIPIb in Mantle Cell Lymphoma
CONCLUSION: p53 expression and CDKN2A deletion represent a reliable pretreatment prognostic factor that identifies patients who do not benefit from currently used immunochemotherapy-based therapies and who are candidates for diversified treatments with the aim of improving prognosis. The MIPIb represents a prognostic index that correlates well with these biological alterations and can be used in clinical practice as their surrogate.PMID:37147150 | DOI:10.1016/j.clml.2023.04.004 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 5, 2023 Category: Cancer & Oncology Authors: Francesco Gaudio Michele Dicataldo Fabrizia Di Giovanni Gerardo Cazzato Antonio d'Amati Tommasina Perrone Pierluigi Masciopinto Filomena Emanuela Laddaga Pellegrino Musto Eugenio Maiorano Giuseppe Ingravallo Source Type: research
SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on Target
Clin Lymphoma Myeloma Leuk. 2023 Apr 19:S2152-2650(23)00134-9. doi: 10.1016/j.clml.2023.04.007. Online ahead of print.ABSTRACTWhile the peripheral T-cell lymphomas (PTCL) remain a therapeutic challenge, and increasingly account for a disproportionate number of lymphoma-related deaths, improved understanding of disease pathogenesis and classification, and the development of novel therapeutic agents over the past decade, all provide reasons for a more optimistic outlook in the next. Despite their genetic and molecular heterogeneity, many PTCL are dependent upon signaling input provided by antigen, costimulatory, and cytokine...
Source: Clinical Lymphoma and Myeloma - May 4, 2023 Category: Cancer & Oncology Authors: Shannon A Carty Carlos A Murga-Zamalloa Ryan A Wilcox Source Type: research
SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on Target
Clin Lymphoma Myeloma Leuk. 2023 Apr 19:S2152-2650(23)00134-9. doi: 10.1016/j.clml.2023.04.007. Online ahead of print.ABSTRACTWhile the peripheral T-cell lymphomas (PTCL) remain a therapeutic challenge, and increasingly account for a disproportionate number of lymphoma-related deaths, improved understanding of disease pathogenesis and classification, and the development of novel therapeutic agents over the past decade, all provide reasons for a more optimistic outlook in the next. Despite their genetic and molecular heterogeneity, many PTCL are dependent upon signaling input provided by antigen, costimulatory, and cytokine...
Source: Clinical Lymphoma and Myeloma - May 4, 2023 Category: Cancer & Oncology Authors: Shannon A Carty Carlos A Murga-Zamalloa Ryan A Wilcox Source Type: research
A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse
CONCLUSION: A short course of Elo-KRd induction followed by Elo-lenalidomide maintenance demonstrated activity in predominantly lenalidomide-refractory and / or high-risk MM. The results with this well-tolerated combination are comparable to other contemporary approved triplet combinations.PMID:37127471 | DOI:10.1016/j.clml.2023.03.016 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 1, 2023 Category: Cancer & Oncology Authors: Manisha Bhutani David M Foureau Myra Robinson Fei Guo Kateryna Fesenkova Shebli Atrash Barry Paul Cindy Varga Reed Friend Mauricio Pineda-Roman Katherine Rigby James T Symanowski Sarah Norek Mallory R Tucker Lawrence J Druhan Peter M Voorhees Saad Z Usman Source Type: research
Autologous Stem Cell Transplant in Lymphoma Using a Noncryopreserved Platform: An Adapted Sequential Conditioning Maintaining Dose Intensity Does not Affect Transplantation Outcomes
CONCLUSION: In conclusion, conditioning adjusted for a noncryopreserved strategy offers at least similar or even better results than the cryopreserved strategy. Prospective studies are warranted.PMID:37127472 | DOI:10.1016/j.clml.2023.04.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 1, 2023 Category: Cancer & Oncology Authors: Mauricio Sarmiento Patricio Rojas Catherine Gutierrez Jacqueline Quezada Veronica Jara James Campbell Garcia Maria None Jose None VicenteSandoval Max Vergara Nicolas Triantafilo Mauricio Ocqueteau Source Type: research
A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
CONCLUSION: This is the first formal prospective trial using infusion times shorter than the standard schedule directly after an initial 4-hours dose. This rapid infusion protocol has resulted in more efficient resource utilization and has become the standard protocol for the use in all intravenous daratumumab regimens in Canada. This approach has been particularly helpful in shortening chair time during the COVID-19 pandemic and providing a useful alternative in jurisdictions without access to subcutaneous daratumumab.PMID:37127473 | DOI:10.1016/j.clml.2023.03.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 1, 2023 Category: Cancer & Oncology Authors: Julie Stakiw Shruthi Kodad Richard LeBlanc Michael Sebag Annette E Hay Vishal Kukreti Julie C ôté Fernando Camacho Molei Fu Engin Gul Donna Reece Source Type: research
